WC
RPRX

Wexford Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

Wexford Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-140,745
Closed -$2.5M – 227
2014
Q1 		$2.5M Sell
140,745
-434,386
-76% -$8.41M 0.19% 82
2013
Q4 		$10.5M Sell
575,131
-649,299
-53% -$12.3M 0.9% 9
2013
Q3 		$32.8M Sell
1,224,430
-42,250
-3% -$905K 2.71% 3
2013
Q2 		$23.4M Buy
+1,266,680
New +$22.4M 2.05% 5

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wexford Capital's RPRX Position: Q2 2014 in Review

Wexford Capital sold out of Repros Therapeutics Inc. (RPRX) in Q2 2014, closing a stake of 140,745 shares — an estimated $2.5M sold.

Wexford Capital first reported a position in RPRX in Q2 2013 and held it in 4 quarters. The position peaked at $32.8M in Q3 2013. 77 funds tracked by Wall St. Rank hold RPRX as of Q2 2014.

  • Wexford Capital reported no remaining Repros Therapeutics Inc. position as of Q2 2014 after selling out during the quarter.
  • Wexford Capital sold 140,745 Repros Therapeutics Inc. shares in Q2 2014, an estimated $2.5M.
  • Wexford Capital first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 4 quarters.
  • Wexford Capital's Repros Therapeutics Inc. position peaked at $32.8M in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2014.

Based on Wexford Capital's 13F filing for Q2 2014, filed 13 Aug 2014.